Entera Bio Ltd. (NASDAQ:ENTX) Sees Large Growth in Short Interest

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 104,500 shares, a growth of 59.5% from the January 31st total of 65,500 shares. Based on an average trading volume of 114,000 shares, the short-interest ratio is currently 0.9 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a research report on Monday, November 11th.

Entera Bio Trading Up 4.3 %

Shares of NASDAQ:ENTX traded up $0.08 during mid-day trading on Monday, reaching $1.93. The stock had a trading volume of 132,440 shares, compared to its average volume of 154,256. Entera Bio has a 1 year low of $1.30 and a 1 year high of $3.35. The business’s 50 day moving average price is $2.30 and its 200 day moving average price is $2.00. The company has a market cap of $69.07 million, a P/E ratio of -7.42 and a beta of 1.52.

Institutional Investors Weigh In On Entera Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENTX. Signature Estate & Investment Advisors LLC purchased a new stake in Entera Bio during the third quarter valued at approximately $90,000. Perigon Wealth Management LLC purchased a new stake in Entera Bio during the fourth quarter valued at approximately $325,000. Northern Trust Corp purchased a new stake in Entera Bio during the fourth quarter valued at approximately $450,000. Parkman Healthcare Partners LLC raised its position in Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after purchasing an additional 9,558 shares during the period. Finally, Knoll Capital Management LLC raised its position in Entera Bio by 51.5% during the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock valued at $12,470,000 after purchasing an additional 2,000,000 shares during the period. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.